This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:publications:applications_orphan_status [03.06.2011] – external edit 127.0.0.1 | home:publications:applications_orphan_status [07.04.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== Applications to the FDA for orphan drug status for Marshall Protocol medications ====== | + | ~~NOTOC~~ |
+ | |||
+ | ====== Applications to the FDA for orphan drug status for Marshall Protocol medications ====== | ||
Autoimmunity Research Foundation has submitted multiple applications to the Office of Orphan Products Development, | Autoimmunity Research Foundation has submitted multiple applications to the Office of Orphan Products Development, | ||
Line 6: | Line 8: | ||
- | * submitted by ARF (September 2005) - [[http:// | + | * submitted by ARF (September 2005) - [[https:// |
- | * FDA approval (March 2006) - [[http:// | + | * FDA approval (March 2006) - [[https:// |
===== Clindamycin ===== | ===== Clindamycin ===== | ||
- | * submitted by ARF (September 2005) - [[http:// | + | * submitted by ARF (September 2005) - [[https:// |
- | * FDA approval (August 2006) - [[http:// | + | * FDA approval (August 2006) - [[https:// |
< | < | ||
Line 20: | Line 22: | ||
===== Olmesartan ===== | ===== Olmesartan ===== | ||
- | * submitted by ARF (July 2006) - [[http:// | + | * submitted by ARF (July 2006) - [[https:// |
* // | * // | ||